The hangover: Caribou's allogeneic CAR-T hit by durability doubts as half of patients relapse

Caribou Biosciences is nursing a hangover. Weeks after celebrating a 100% overall response rate, the CRISPR biotech has revealed 50% of patients relapsed within six months of receiving its allogeneic CAR-T cell therapy, sending shares into a sudden 13% dive that largely erased earlier gains.